Unknown

Dataset Information

0

Anaemia management with C.E.R.A. in routine clinical practice: OCEANE (Cohorte Mircera patients non-dialyses), a national, multicenter, longitudinal, observational prospective study, in patients with chronic kidney disease not on dialysis.


ABSTRACT: The aim of this study was to describe the management of anaemia with a continuous erythropoietin receptor activator (C.E.R.A., methoxy polyethylene glycol epoetin-β), in patients with chronic kidney disease (CKD) not on dialysis, naïve or non-naïve to treatment with erythropoiesis-stimulating agents (ESAs) at inclusion. National, multicentre, longitudinal, observational prospective study. 133 nephrologists practicing in France selected patients during their routine follow-up visits. The study was non-interventional. They were adult CKD patients not on dialysis or kidney transplant patients, naïve or not to ESA treatment: 524 patients not on dialysis (48% ESA-naïve) and 92 kidney transplant patients (24% ESA-naïve) were included and followed up every 3 months during 1 year. The two main endpoints were the percentage of patients who achieved target haemoglobin (Hb) levels as per European Medicines Agency guidelines (10-12 g/dl) around 6 months of treatment and modalities of treatment. Approximately one in two patients had an Hb level within 10-12 g/dl at baseline, and around 6 and 12 months of treatment. Ninety per cent of ESA-naïve patients achieved at least +1 g/dl increase over baseline Hb levels or had Hb within 10-12 g/dl around 6 and 12 months. The Hb level remained at approximately 11.5 g/dl during the 12 months of follow-up. Around 6 months: almost all patients were receiving a once-monthly subcutaneous dose of C.E.R.A. (patients not on dialysis: 95±54 µg; kidney transplant patients: 121±70 µg); approximately half the patients did not require a change in C.E.R.A. dose. Adverse effects related to C.E.R.A. were observed in less than 5% of patients and led to modification or discontinuation of treatment in 2%. The efficacy and safety of C.E.R.A. in CKD patients not on dialysis, with or without kidney transplantation, were confirmed in routine clinical practice.

SUBMITTER: Frimat L 

PROVIDER: S-EPMC3612788 | biostudies-literature | 2013 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Anaemia management with C.E.R.A. in routine clinical practice: OCEANE (Cohorte Mircera patients non-dialyses), a national, multicenter, longitudinal, observational prospective study, in patients with chronic kidney disease not on dialysis.

Frimat Luc L   Mariat Christophe C   Landais Paul P   Koné Sébastien S   Commenges Bénédicte B   Choukroun Gabriel G  

BMJ open 20130309 3


<h4>Objective</h4>The aim of this study was to describe the management of anaemia with a continuous erythropoietin receptor activator (C.E.R.A., methoxy polyethylene glycol epoetin-β), in patients with chronic kidney disease (CKD) not on dialysis, naïve or non-naïve to treatment with erythropoiesis-stimulating agents (ESAs) at inclusion.<h4>Design</h4>National, multicentre, longitudinal, observational prospective study.<h4>Setting</h4>133 nephrologists practicing in France selected patients duri  ...[more]

Similar Datasets

| S-EPMC10817843 | biostudies-literature
| S-EPMC11782378 | biostudies-literature
| S-EPMC2390949 | biostudies-literature
| S-EPMC7411551 | biostudies-literature
| S-EPMC7607125 | biostudies-literature
| S-EPMC8475152 | biostudies-literature
| S-EPMC10543527 | biostudies-literature
| S-EPMC8964893 | biostudies-literature
| S-EPMC9747730 | biostudies-literature
| S-EPMC4403744 | biostudies-literature